311 related articles for article (PubMed ID: 2452983)
1. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.
Gabrilove JL; Jakubowski A; Scher H; Sternberg C; Wong G; Grous J; Yagoda A; Fain K; Moore MA; Clarkson B; Oettgen HF; Alton K; Welte K; Souza L
N Engl J Med; 1988 Jun; 318(22):1414-22. PubMed ID: 2452983
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human granulocyte colony stimulating factors: therapeutic application in the prevention of chemotherapy-induced neutropenia.
Gabrilove JL; Jakubowski A; Scher H; Sternberg C; Wong G; Grous J; Yagoda A; Fain K; Moore MA; Clarkson B
Behring Inst Mitt; 1988 Aug; (83):229-33. PubMed ID: 2467654
[No Abstract] [Full Text] [Related]
3. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
[TBL] [Abstract][Full Text] [Related]
4. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
[TBL] [Abstract][Full Text] [Related]
5. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
Igawa M; Kadena H; Ueda M; Usui T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732
[TBL] [Abstract][Full Text] [Related]
6. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
[TBL] [Abstract][Full Text] [Related]
7. M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produced by rhG-CSF.
Ueda M; Igawa M; Kadena H; Usui T
Int J Urol; 1994 Sep; 1(3):223-7. PubMed ID: 7542154
[TBL] [Abstract][Full Text] [Related]
8. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
Seidman AD; Scher HI; Gabrilove JL; Bajorin DF; Motzer RJ; O'Dell M; Curley T; Dershaw DD; Quinlivan S; Tao Y
J Clin Oncol; 1993 Mar; 11(3):408-14. PubMed ID: 7680373
[TBL] [Abstract][Full Text] [Related]
9. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
[TBL] [Abstract][Full Text] [Related]
10. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
Logothetis CJ; Dexeus FH; Sella A; Amato RJ; Kilbourn RG; Finn L; Gutterman JU
J Natl Cancer Inst; 1990 Apr; 82(8):667-72. PubMed ID: 2181151
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of chemotherapeutic effects by recombinant human granulocyte colony-stimulating factor on implanted mouse bladder cancer cells (MBT-2).
Akaza H; Fukushima H; Koiso K; Aso Y
Cancer; 1992 Feb; 69(4):997-1002. PubMed ID: 1370920
[TBL] [Abstract][Full Text] [Related]
12. [Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy--phase I study].
Fukutani H; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Tabata M; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1989 May; 16(5):2005-12. PubMed ID: 2471461
[TBL] [Abstract][Full Text] [Related]
13. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
Conti JA; Scher HI
Cancer; 1992 Dec; 70(11):2699-702. PubMed ID: 1384952
[TBL] [Abstract][Full Text] [Related]
14. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
Noguchi S; Kubota Y; Shuin T; Hosaka M; Miura T; Kondoh I
Int J Urol; 1994 Jun; 1(2):140-2. PubMed ID: 7543010
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
Bronchud MH; Scarffe JH; Thatcher N; Crowther D; Souza LM; Alton NK; Testa NG; Dexter TM
Br J Cancer; 1987 Dec; 56(6):809-13. PubMed ID: 2829955
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis.
Bonilla MA; Gillio AP; Ruggeiro M; Kernan NA; Brochstein JA; Abboud M; Fumagalli L; Vincent M; Gabrilove JL; Welte K; Souza LM; O'Reilly RJ
N Engl J Med; 1989 Jun; 320(24):1574-80. PubMed ID: 2471075
[TBL] [Abstract][Full Text] [Related]
18. Effects of the in vivo administration of recombinant human granulocyte colony-stimulating factor following cytotoxic chemotherapy on granulocytic precursors in patients with malignant lymphoma.
Ema H; Suda T; Sakamoto S; Tomonaga T; Tsunoda J; Muroi K; Komatsu N; Miwa A; Ohsaka A; Yoshida M
Jpn J Cancer Res; 1989 Jun; 80(6):577-82. PubMed ID: 2474526
[TBL] [Abstract][Full Text] [Related]
19. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
Herrmann F; Schulz G; Wieser M; Kolbe K; Nicolay U; Noack M; Lindemann A; Mertelsmann R
Am J Med; 1990 Jun; 88(6):619-24. PubMed ID: 2189305
[TBL] [Abstract][Full Text] [Related]
20. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
